• Dehydroabietic Acid: Dual PPAR-α/γ Agonist for Metabolic Res

  2026-04-22

  Dehydroabietic acid is a natural dual PPAR-α/γ agonist, optimized for precise modulation of lipid metabolism and insulin sensitivity. This guide translates recent metabolic research breakthroughs into actionable workflows, troubleshooting strategies, and comparative advantages for metabolic disorder studies.

• Praeruptorin A: Multi-Targeted Angular Pyranocoumarin for In

  2026-04-22

  Praeruptorin A is an angular pyranocoumarin compound with well-characterized anti-inflammatory, anti-ferroptotic, and anti-metastatic activities. Its efficacy and low cytotoxicity in preclinical models support use as a research tool for ulcerative colitis, cancer metastasis, and cardiomyopathy studies. Data-backed protocols and mechanistic insights position Praeruptorin A as a reproducible standard for pathway-targeted experimentation.

• Mitochondrial ROS, Apoptosis, and Muscle Atrophy in Ovarian

  2026-04-21

  This study investigates how mitochondrial-linked apoptosis and necroptosis contribute to skeletal muscle atrophy in a mouse model of metastatic ovarian cancer. The results show that while SkQ1 suppresses mitochondrial ROS and caspase activity, it does not prevent muscle fiber atrophy, highlighting a disconnect between apoptosis regulation and atrophic outcomes in this context.

• Bufalin Targets STK33: Mechanistic Advances in TNBC Therapy

  2026-04-21

  This article reviews a recent study identifying serine/threonine kinase 33 (STK33) as a direct target of Bufalin in triple-negative breast cancer (TNBC). The findings position Bufalin as a unique apoptosis inducer and protein degrader in TNBC, opening mechanistic and translational avenues for oncology researchers.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi

  2026-04-20

  This study identifies a mechanistic link between endocannabinoid-mediated CB1 signaling and glutamate transporter GLT-1 regulation after traumatic brain injury (TBI). By upregulating GLT-1 and inhibiting the CB1-CREB pathway, neuronal apoptosis and cognitive deficits in TBI mice are attenuated, suggesting new neuroprotective strategies for secondary brain injury.

• CHK1 Inhibition in Breast Cancer: Impact of ER/PR Status on

  2026-04-20

  This study elucidates how CHK1 inhibition in breast cancer produces divergent effects based on estrogen and progesterone receptor status. The findings highlight the molecular basis for stratified therapeutic strategies and underscore the importance of tumor heterogeneity in optimizing targeted interventions.

• Applied Strategies for (-)-Norepinephrine (+)-bitartrate in

  2026-04-19

  (-)-Norepinephrine (+)-bitartrate is the gold-standard adrenergic agonist for inducing robust cardiovascular phenotypes and dissecting adrenergic signaling pathways. This article delivers practical workflows, troubleshooting insights, and evidence-based protocol enhancements for maximizing reproducibility in cardiomyopathy and blood pressure regulation studies.

• A-769662: Redefining AMPK Activation and Autophagy Control

  2026-04-18

  Discover how A-769662, a potent AMPK activator, is reshaping the understanding of cellular energy regulation and autophagy suppression. This article provides a distinct, evidence-based perspective for advanced metabolic research.

• Disrupting c-MYC-G9a Axis: Dual BRD4-RAC1 Inhibition in Brea

  2026-04-17

  This study demonstrates that simultaneous inhibition of BRD4 and RAC1 disrupts the c-MYC–G9a–FTH1 axis and downregulates HDAC1, leading to reduced growth, stemness, and tumorigenesis across breast cancer subtypes. The findings clarify epigenetic regulatory mechanisms and support the use of G9a histone methyltransferase inhibitors in translational cancer research.

• Penicillin G Sodium: Precision Dosing, Stability, and Transl

  2026-04-16

  Explore the advanced science of Penicillin G Sodium, a natural penicillin antibiotic, with a focus on dosing optimization, stability, and translational research. Gain unique insights on protocol design and practical assay decisions, grounded in recent evidence.

• Carbapenemase Gene Dynamics in CREC During the COVID-19 Era

  2026-04-15

  This study systematically characterized carbapenemase-encoding gene (CEG) prevalence, genetic localization, and horizontal transfer in carbapenem-resistant Enterobacter cloacae from hospitals in Guangdong, China, during the COVID-19 pandemic. The findings highlight the dominant role of plasmid-borne blaNDM-1 genes in driving multidrug resistance, with significant implications for epidemiological surveillance and resistance modeling.

• Deracoxib (SKU B1091): Reliable COX-2 Inhibition for Lab Ass

  2026-04-14

  This article presents scenario-driven guidance for researchers using Deracoxib (SKU B1091) as a selective COX-2 inhibitor in cell viability, inflammation, and cancer biology assays. It integrates evidence-backed protocol parameters, comparative vendor insights, and experimental troubleshooting to ensure reproducibility and data confidence when using Deracoxib in the laboratory.

• YAP-TEAD Pathway Mediates PPARα-Driven Liver Regeneration in

  2026-04-13

  This study elucidates the mechanistic link between PPARα activation and hepatic regeneration, highlighting the critical role of the YAP-TEAD pathway in WY-14643-induced hepatomegaly in mice. These findings provide a framework for dissecting nuclear receptor cross-talk in liver growth and metabolic disorder research.

• Selective Spectrophotometric Analysis of Phenolic β-Lactam A

  2026-04-12

  The reference study by Salem and Saleh introduces two rapid, selective spectrophotometric methods for quantifying phenolic β-lactam antibiotics—including amoxicillin—in both pure forms and pharmaceutical formulations. These approaches overcome common limitations of chromatographic and less selective analytical techniques, enabling robust assessment of amoxicillin even in the presence of structurally related penicillins such as dicloxacillin.

• Amyloid Beta-peptide (25-35): Applied Models in Alzheimer’s

  2026-04-12

  Amyloid Beta-peptide (25-35) (Aβ25-35) is the benchmark fragment for modeling amyloid-induced neurotoxicity and microglial polarization in Alzheimer’s disease research. This article details advanced workflows, troubleshooting strategies, and actionable integration of recent mechanistic findings, empowering neurodegeneration studies with reproducibility and translational insight.

15905 records 1/1061 page Next 12345 下5页 Last page